Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation (AGTC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
agtc · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Applied Genetic Technologies CorporationYou AGTC | — | N/A | — | -$1.59 |
 Allakos Inc. ALLK | $30M | N/A | — | -$1.30 |
 Angion Biomedica Corp. ANGN | $30M | N/A | — | -$2.58 |
 Axcella Health Inc. AXLA | $13M | N/A | — | -$1.27 |
 Elevation Oncology, Inc. ELEV | $22M | N/A | — | -$0.78 |
 Freeline Therapeutics Holdings plc FRLN | $28M | N/A | — | -$22.52 |
 Harpoon Therapeutics, Inc. HARP | $865M | N/A | — | -$20.24 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Applied Genetic Technologies Corporation (AGTC) measures how much investors pay for each dollar of the company's trailing earnings. AGTC's current PE ratio of N/A is calculated by dividing its stock price of $0.39 by its TTM earnings per share of -$1.59.
Frequently asked questions
AGTC pe ratio · 6 questionsAGTC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.39 and TTM EPS of -$1.59. Data sourced from Financial Modeling Prep via AGTC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Applied Genetic Technologies Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09